The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan)

Abstract

We assessed the prevalence and incidence of Systemic Lupus Erythematosus (SLE) in 2010 in adults from four cities in Russia, Kazakhstan and Ukraine. Individuals with SLE were identified retrospectively from the medical records of specialized centers. Prevalent SLE patients were nondeceased city residents, diagnosed prior to December 31, 2010; incident patients were residents newly diagnosed between January 1 and December 31, 2010. Population size was obtained from official census data. The observed prevalence rates (per 100,000, 95% CI) were 9.0 (7.1-11.2) in Kursk and Yaroslavl, Russian Federation; Kazakhstan; in Vinnitsa, Ukraine. The cumulative incidence rates (per 100,000, 95% CI) were 1.4 (0.7-2.4); 1.6 (0.4-4.1) and 0.3 (0.0-1.8), correspondingly. All rates were higher among females compared to males, and incidence peaked in the population aged 25-44. These rates appear slightly lower than those reported from Western Europe and the USA. This could be because of study design (case-ascertainment), local health care practices or true differences in disease risk. Case age and sex distribution was similar to the known epidemiology of SLE. The rates were highest in Kazakhstan, likely because of a predominantly ethnic Asian population. Lupus (2014) 23, 213-219.

The clinical course and standard therapy of systemic lupus erythematosus in the Russian Federation

“…Сле-довательно, с большой долей вероятности можно утвер-ждать, что у достаточно большого количества больных забо-левание остается недиагностированным или диагноз уста-новлен неправильно. Это также может объяснять низкую распространенность (по установленному диагнозу) СКВ, о чем сообщалось в нашей предыдущей публикации [12].…”

“…Данные этого иссле-дования позволяют получить представление о заболеваемо-сти и распространенности СКВ [12].…”

“…Данная публикация касается российских пациентов, которые наблюдались в 6 российских центрах (Москва, Санкт-Петербург, Воронеж, Екатеринбург, Курск, Яро-славль). План исследования представлен в нашей предыду-щей публикации [12]. Исследователи получали данные из историй болезни пациентов, используя стандартную форму, которая включала следующую информацию: демографиче-ские и исходные характеристики, активность СКВ, лабора-торно-инструментальные исследования, лечение и потреб-ляемые ресурсы здравоохранения.…”

Pharmacoeconomic evaluation of targeted therapy in patients with systemic lupus erythematosus

“…According to pooled results from epidemiological trials conducted in Europe and the United States in 1950-2006, the average prevalence of SLE was about 50 per 100,000 population [1]. In Russia, according to epidemiological studies conducted in Yaroslavl and Kursk, it was shown that the prevalence of SLE in these regions is about 9 per 100,000 population which is much less than in Europe [18]. Currently, an increase in SLE incidence is being recorded, which is thought to be associated with improvement in rheumatic diseases detection [5].…”

Lupus around the world

“…7 An Australian survey found a prevalence of 95 per 100,000 in the indigenous peoples compared with 45 per 100,000 in the non-indigenous population. 8 In addition, with this higher prevalence in certain ethnic groups, there was frequent evidence of more serious disease.…”